Advertisement
Screener

MYRIAD GENETICS, INC. (MYGN) Payments for Software

2.8 / 5 stars · 68/120 Roast Me

MYRIAD GENETICS, INC. Payments for Software

MYRIAD GENETICS, INC. (MYGN) reported Payments for Software of $10.70 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-28.

Financial Statements › Cash Flow › Financing Activities

us-gaap:PaymentsForSoftware · last filed 2025-02-28

  • MYRIAD GENETICS, INC. payments for software for the quarter ending 2024-12-31 was $2.30M, a 34.29% decline year-over-year.
  • MYRIAD GENETICS, INC. payments for software for the quarter ending 2024-09-30 was $2.80M, a 57.58% decline year-over-year.
  • MYRIAD GENETICS, INC. payments for software for the quarter ending 2024-06-30 was $3.70M.
  • MYRIAD GENETICS, INC. payments for software for the quarter ending 2024-03-31 was $1.90M.
  • MYRIAD GENETICS, INC. payments for software for fiscal 2024 was $10.70M, a 5.94% increase from fiscal 2023.
  • MYRIAD GENETICS, INC. payments for software for fiscal 2023 was $10.10M.
  • MYRIAD GENETICS, INC. payments for software for fiscal 2022 was $0.00.
  • MYRIAD GENETICS, INC. payments for software for fiscal 2021 was $0.00.
Period endPayments for Software 3 monthPayments for Software 6 monthPayments for Software 9 monthPayments for Software 12 month
2024-12-31$2.30M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28
$5.10M
derived: sum of 2 quarters · filed 2025-02-28
$8.80M
derived: sum of 3 quarters · filed 2025-02-28
$10.70M
10-K · filed 2025-02-28
2024-09-30$2.80M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08
$6.50M
derived: sum of 2 quarters · filed 2024-11-08
$8.40M
10-Q · filed 2024-11-08
$11.90M
derived: sum of 4 quarters · filed 2025-02-28
2024-06-30$3.70M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07
$5.60M
10-Q · filed 2024-08-07
$9.10M
derived: sum of 3 quarters · filed 2025-02-28
$15.70M
derived: sum of 4 quarters · filed 2025-02-28
2024-03-31$1.90M
10-Q · filed 2024-05-08
$5.40M
derived: sum of 2 quarters · filed 2025-02-28
$12.00M
derived: sum of 3 quarters · filed 2025-02-28
$12.00M
derived: sum of 4 quarters · filed 2025-02-28
2023-12-31$3.50M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28
$10.10M
derived: sum of 2 quarters · filed 2025-02-28
$10.10M
derived: sum of 3 quarters · filed 2025-02-28
$10.10M
10-K · filed 2025-02-28
2023-09-30$6.60M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08
$6.60M
derived: sum of 2 quarters · filed 2024-11-08
$6.60M
10-Q · filed 2024-11-08
$6.60M
derived: sum of 4 quarters · filed 2025-02-28
2023-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07
$0.00
10-Q · filed 2024-08-07
$0.00
derived: sum of 3 quarters · filed 2025-02-28
2023-03-31$0.00
10-Q · filed 2024-05-08
$0.00
derived: sum of 2 quarters · filed 2025-02-28
2022-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28
$0.00
10-K · filed 2025-02-28
2022-09-30$0.00
10-Q · filed 2023-11-07
2021-12-31$0.00
10-K · filed 2024-02-28

Similar stocks

Stock NameCountryMarket CapPE Ratio
Alpha Teknova, Inc. (TKNO)United States$0.500B-18.12
Insight Molecular Diagnostics Inc. (IMDX)United States$0.129B-3.90
IMMUCELL CORP /DE/ (ICCC)United States$0.091B116.10
QuidelOrtho Corp (QDEL)United States$0.733B-0.90
BIOMERICA INC (BMRA)United States$0.011B
Q/C TECHNOLOGIES, INC. (QCLS)United States$0.008B-1.93
Cardio Diagnostics Holdings, Inc. (CDIO)United States$0.006B
VOLITIONRX LTD (VNRX)$0.003B-0.64
ACHIEVE LIFE SCIENCES, INC. (ACHV)United States$0.806B-5.88
Intellia Therapeutics, Inc. (NTLA)United States$1.705B-5.92